Leadership team


Chief Executive Officer

La Corte

Group Chief
Financial Officer


Executive VP
Specialty & Primary
Care Business Unit


Executive VP Rare
Diseases Business Unit


Group Chief
Legal Officer


Group Chief
People and Culture


Executive VP
Corporate Development,
Licensing & Innovation


Executive VP
Research & Development


Chief Medical


Executive VP Group
Industrial Operations

Corporate staff






Audit Director


Group Transformation
& Integration Director


Group People
Engagement & Change
Management Director


Group Corporate Law
Counsel and Secretary
of the Board of Directors
of Recordati S.p.A


VP Head of
Investor Relations

Robert Koremans

Chief Executive Officer

Rob Koremans, qualified as Medical Doctor from RSM Erasmus University in the Netherlands and Executive MBA in US, has over 30 years’ experience in managerial and executive roles, gained mainly in the pharmaceutical industry at various international companies.


In 1988 he started his professional career at Sanofi in the Netherlands as Product Manager, then being appointed as Head of Cardiovascular Unit.


In 1990, he joined Excerpta Medica Medical Communications, part of Elsevier Group, as International Business Development Director. After one year experience as Marketing & Service Manager at J&J Cilag International in Switzerland, in 1993 he joined Serono Group where he covered different positions with growing responsibilities: he was first General Manager at Ares-Serono in the Netherlands, then Managing Director at Serono Germany and finally Vice President Europe based in Switzerland.


In 2000, he joined Grunenthal as Head of Area Management Europe & USA and Head of Global Marketing, being then appointed Member of the Executive Board.


In 2007, he became Chief Executive Officer and co-owner at Cryo-Save Group, Europe’s leading stem cell storage company; two years later, he was appointed as President and CEO of Zentiva, part of the Sanofi-Aventis Group, in Czech Republic.


In 2012, he joined Teva Pharmaceutical Industries (TPI) as Member of TPI Executive Committee and President & CEO of Teva Pharmaceuticals Europe, then becoming President & CEO Global Specialty Medicines. Finally, in 2018 he joined Nutreco, global leader in animal nutrition, aqua culture and alternative proteins, as Chief Executive Officer.


In December 2021 he joined Recordati as Chief Executive Officer.

Luigi La Corte

Group Chief Financial Officer
Luigi La Corte has a degree cum laude in Economics and Business (with major in Economics) from LUISS University in Rome and a professional qualification as Fellow of the Chartered Institute of Management Accountants; he has a wide experience in international finance roles, a large part of which spent in the pharmaceutical industry.

In 1993 he started his professional career at Procter & Gamble, where he covered different financial positions with growing responsibilities: Financial Analyst in Belgium, Capital Markets Manager at regional level and finally Group Manager Financial Planning and Analysis for the Nordics. In 1998 he moved to PepsiCo as International Corporate Finance Manager, to support Europe and Middle East businesses. After some years as Consultant at Bain & Company Italy, in 2004 he moved to Alliance Unichem’s pharmaceutical wholesaler and distribution business in Italy as Finance & Administration Director.

In 2005 he joined AstraZeneca as Chief Financial Officer of the Italian Subsidiary, becoming Regional Finance Director for the Asia-Pacific region and finally being appointed VP Finance for Global Commercial Organization, and subsequently taking on financial responsibilities for the Global Product & Portfolio Strategy Unit.

In 2014 he joined GlaxoSmithKline as SVP Finance for the global Pharma R&D organization, taking later on also the responsibility of Head of Global Business Development. Finally, in 2017, he joined pladis group, a leading snack and confectionary company, as Chief Financial Officer.

In November 2019 he joined Recordati as Group Chief Financial Officer.

Alberto Martinez

Executive VP Specialty & Primary Care Business Unit

Alberto Martinez has a PhD in Pharmacy and an Executive MBA with about twenty years of experience in the pharmaceutical industry.

After the initial activity as Sales Representative and Product Manager at Janssen, in 2003 he joined Mundipharma, where he covered different positions with growing responsibilities both at local and European level: he started his professional path as European Product Manager becoming, in 2006, European Marketing Manager.

One year later he was appointed General Manager at Mundipharma Spain, then widening his responsibilities to Portugal, As of 2014, he was at the same time Managing Director at Napp Pharmaceuticals in UK and Regional Director Northern Europe Mundipahrma.

In 2016, he was appointed European Director Commercial Operations and finally, one year later, President and Chief Executive Officer Europe, with global responsibility including R&D, manufacturing and supply chain.

In January 2021 he joined Recordati as Executive Vice President Specialty and Primary Care Business Unit.

Scott Pescatore

Executive VP Rare Diseases Business Unit
Scott Pescatore has a doctorate in Pharmacy and Oncology Drug Development with twenty years of experience in the pharmaceutical industry.

In 2001 after completing his post-doctoral fellowship at University of North Carolina Chapel Hill and GlaxoSmithKline, he joined Novartis Oncology where he spent most of his career covering different positions with growing responsibilities in Clinical Research, Sales & Marketing and General Management both in the US market, Global and at the European level.

In the US Oncology Business Unit he was Senior Clinical Research Scientist and then moved to commercial business becoming Senior Sales Specialist, Senior Manager Business Analytics and finally Senior Brand Manager Haematology for US and Global Marketing.

In 2008 he moved to the United Kingdom with Novartis Oncology as New Products Strategy Head and one year later was appointed Business Franchise Head of Oncology Solid Tumours. In 2010 he relocated to Italy as Marketing Director Region Europe for Haematology and in 2014 was appointed General Manager of the Oncology Business Unit in Ireland. In 2016 he was appointed General Manager Region Europe for the Rare Diseases Business Unit based in Italy. In 2018 after 17 years with Novartis Oncology, he joined AstraZeneca Italy as Vice President and Head of the Oncology Business Unit.

In February 2020 he joined Recordati as Vice President & Head of Global Operations Rare Diseases.

In January 2022 he was appointed Vice President and Director for the Orphan Drugs Business.

Bibianne Bon

Group Chief Legal Officer
Bibianne Bon has a degree in European, International and Dutch law from the University of Groningen, the Netherlands and has over 20 years’ experience in the legal profession. She began her career in the international law firm Allen & Overy LLP in Amsterdam where she specialized in M&A, corporate and commercial law. Bibianne joined Teva Pharmaceutical Industries in 2010 and initially focused on corporate law and governance matters; she has worked on many of Teva’s mergers and acquisitions. Over the years she gained a broad experience with pharma related legal and compliance matters. She was appointed Sr. Dir General Counsel Corporate EU & Benelux in 2014.

In 2017, Bibianne was appointed Sr VP & General Counsel Europe. During her tenure, she led her team through a significant restructuring while supporting the business and navigating some major challenges. She worked on complex governmental investigations into new policy areas and material litigations on novel areas of law.

In April 2023 she joined Recordati as Group Chief Legal Officer.

Alessandra Abate

Group Chief People and Culture Officer

Alessandra Abate is a philologist and holds a degree cum laude in Foreign Languages and Literature from La Sapienza University in Rome and an MBA from LUISS University; passionate for transformative leadership and scientific innovation she has a wide experience in change leadership and business model transformation.


Alessandra started her professional career at Merck Sharp & Dohme in Italy in 1999 in Product Management and held commercial roles of increasing responsibility up to the appointment to Marketing Director EMEA & Canada. In 2009 she moved to Switzerland and joined Amgen as Brand Director International, with a mandate to launch the first biologic therapy in Primary Care across all ex-US geographies, and leading a cross-functional team within a joint venture with GSK.


In 2012 she joined Boehringer Ingelheim’s HQ in Germany as Global Head, Planning and Innovation supporting the Chief Marketing Officer and the CEO in the design and roll out of a company-wide integrated business planning process.


In 2014 Alessandra joined the leadership and advisory consulting firm Russell Reynolds Associates in their Amsterdam hub as pharmaceuticals expert and core member of the firm’s healthcare team. She was appointed Managing Director and Global Practice Leader, Biotech & Pharmaceuticals in 2019. After moving to Milan, in 2022, she took over the responsibility of the Italian organization and was appointed Amministratore Delegato.


In March 2024 she joined Recordati as Grup Chief People and Culture Officer.

Gabriele Finzi

Executive VP Corporate Development & Licensing

Gabriele Finzi holds a degree in Business Administration with major in Corporate Finance from the Bocconi University (Milan). After an initial experience in investment banking, he began his corporate career as an M&A Analyst at Barilla, where he took part in a number of deals.

In 2005, he joined Siemens Italy to set up the local M&A department; subsequently he became responsible for the financial planning of the South West Europe region of Siemens Medical Solutions.


In 2008 he joined the Corporate Development department at Recordati where he has been assigned increasing responsibilities and has completed several acquisitions; he was appointed Group Business Development Director in 2012, Vice President Corporate Development in 2016 and Vice President Corporate Development & Licensing in 2019.


Since 2022 he takes the responsibility also for the Innovation activities of the Group, in the role of Executive Vice President Corporate Development, Licensing & Innovation.

Milan Zdravkovic

Executive Vice President of Research & Development

Milan Zdravkovic, a Danish national, brings a wealth of experience to his new role, with an impressive track record in developing innovative compounds and leading R&D organizations within the pharmaceutical industry.


His expertise spans a wide range of therapeutic areas, including diabetes, obesity, immunology, hematology, and infectious diseases, and with experience from both rare and non-rare diseases. He has 25 years of life-science experience and has worked at pharma and biotech companies like Novo Nordisk, SOBI-Swedish Orphan Biovitrum and SNIPR Biome, holding increasingly senior roles including Head of R&D and Chief Medical Officer. 

Raffaele Sabia

Chief Medical Officer

Raffaele Sabia holds a degree in Medicine and a post-graduate diploma in Cardiovascular and has a long and rich experience in R&D roles in the pharmaceutical business.

In 1990 he started his professional career at Schwarz Pharma as Medical Adviser for the Cardiovascular area and then became Clinical Research Manager.

In 1997 he moved to AstraZeneca, where he covered different medical roles with growing responsibilities: first he was Senior Clinical Adviser Cardiovascular Area, then Medical Manager Cardiovascular & Metabolic Therapy Areas, later on Medical Affairs Director Primary Care, Neuroscience & Hospital; in 2006 he became, at Headquarters level, European Medical Affairs Director for the Cardiovascular Area.

In the following year, as a part of the same Group, he came back to Italy as Vice President Medical, then Vice President Medical & Regulatory, and finally in 2012 Vice President Medical, Regulatory & Market Access, in charge of the management of Medical Affairs, Clinical Research, Drug Safety, Regulatory Affairs and Market Access Departments.

Finally, in 2013 he joined Novartis Headquarters as Medical Head Region Europe – Cardio Metabolic Franchise, in charge for the entire region of design and implementation of the strategic clinical development and medical affairs programs related to Cardio Metabolic compounds.
During his career he gained a significant experience in different therapeutic areas (Cardiovascular, Metabolic, Gastrointestinal, Respiratory, Neuroscience, Oncology, Anesthesiology, Anti-infective, Vaccines) and contributed to the success of several products.

In July 2017 he joined Recordati S.p.A. as Director of Research and Development.

Roberto Teruzzi

Executive VP Group Industrial Operations

Roberto Teruzzi, who holds a degree in veterinary medicine and two international MBAs, has thirty years of experience in managerial roles in the pharmaceutical business.

In 1986 he started his professional career in Boehringer Mannheim, in R&D and then in Commercial area. He covered different roles with growing responsibilities in various pharmaceutical companies: as of 1989 he was International Product Manager at Farmitalia Carlo Erba, in 1992 he moved to Zambon as Business Development Manager and in 1994 he joined Pharmacia & Upjohn as International Markets Manager.

In 1998 he was in charge of establishing the Italian subsidiary of Ratiopharm, becoming Managing Director of the Company. In 2005 he moved to Alliance Boots, where he established the Almus and Alvita Companies, for the commercialization of generics and para-pharmaceutical products in South Europe, becoming General Manager Europe Almus & Alvita and Managing Director of Almus Italy and Alvita Italy.

In 2008 he joined Mipharm as Chief Operating Officer, responsible for Commercial, Logistics, Distribution and R&D activities; after the transfer of commercial activities to Novartis he was in charge of the production plant, with main responsibility of maximizing profitability.

Finally, in 2010, he moved to Corvette Group (acquired by Recipharm in 2014) as Chief Executive Officer to coordinate Biologici Italia Laboratories, Edmond Pharma and Liosintex, companies operating in third parties manufacturing and development of pharmaceutical products as well as in commercial activities.

In April 2015 he joined Recordati as Executive Vice President of Group Industrial Operations.

Stefania Pesce

ESG Manager
Stefania Pesce has a Degree in Economics from the Università degli Studi di Urbino and a Master in Business Administration from the Business School “Il Sole 24 ORE”. She has spent more than fifteen years working on Sustainability, both in Advisory and in listed companies. After initial Marketing experience at Pirelli, in 2006 she joined KPMG Advisory, becoming Manager within the Sustainability Business Unit. In 2016 she then joined Moncler as Sustainability Manager, in charge of the development of the sustainability strategy, including the definition of the sustainability plan, and implementation of several projects. In July 2020 she joined Recordati as ESG Manager.

Laura Conti

Group Communications Director

Laura Conti is a graduate in foreign languages and literature from Università Cattolica del Sacro Cuore in Milan. She has two post-degree masters, one in business communications and one in journalism.

Laura has more than 20 years of experience in listed companies and international environments and has dealt with almost all aspects of corporate communication, internal and external: from wide-reaching organizational projects to company rebranding and cultural change. She has worked in a range of different industries, including banking, hospitality, digital payments, and e-learning.

Laura joined Recordati in 2022 as Group Internal Communications Director, expanding the role in 2023 and gaining responsibility for external communication. She reports directly to the CEO.

Passionate about humanitarian aid efforts, Laura is also an active volunteer for the Italian Red Cross.

Giovanni Minora

Group Audit
Giovanni Minora holds a degree in Business Economics from the Bocconi University of Milan. He started his professional career in 1995 as junior controller at Alcanital Services, then he worked at Alcan Alluminio as assistant to the financial manager. In 2000 he pursued a career in management in the auditing field: he was appointed Senior Internal Auditor at Foster Wheeler Italiana and later he joined Edison as Operations Auditing team coordinator. In 2005 he joined IT Holding S.p.A as head of Audit and Internal Control for the group. He joined Recordati in 2007 and is currently Group Audit & Compliance.

Angelo Siciliano

Group Transformation & Integration Director

Angelo Siciliano has more than 15 years’ experience across different industrial sectors and geographies.


He joined Recordati in 2015 as Responsible of Corporate Organizational Development, after working in management consulting on various global positions.


He previously held a range of operational roles at Fiat Research Center, Dallara Automobiles, Maserati Racing Team and Italcementi, before moving to Accenture where he developed expertise in running PMI, global transformation and operational excellence programs in Roche, GSK and other multinational companies from non-pharma sectors.


Angelo gained a master’s degree in mechanical engineering with specializations in automotive design and biomechanics and a master in production management at Polytechnic University of Milan.


Since 2014 Angelo is certified master black belt in Lean Manufacturing.

Maria Lamelas

Group People Engagement & Change Management Director

Maria Lamelas graduated in Political Economics and obtained a Master Degree in Econometrics. She brings 20+ years of working experience in different sectors. She started working as an Economist for the Italian Government while teaching economics at University. After some years, she joint Spencer Stuart, a multinational consulting company in the Executive Search, where she worked for 10 years in assignments across Europe. In 2017 she joint Webuild, a multinational player in the infrastructure industry, growing fast through acquisitions. She grew in the Global Human Resources up to her last position as for the Group and VP HR for their Subsidiary US. She has been a key player in their cultural and organizational transformation process.


She joined Recordati in 2023 as People Engagement and Change Management Director, supporting the group’s cultural evolution.

Silvia Signoretti

Group Corporate Law Counsel and Secretary
of the Board of Directors of Recordati S.p.A
Silvia Signoretti is an Italian qualified lawyer with more than 20 years of experience (both in law firms and in-house). After graduating in law at the Padua University, she obtained a master’s degree in law and economy at Luiss Guido Carli University.

She first gained significant professional experience in the field of M&A transactions, corporate law and capital markets matters at Pirola Pennuto Zei & Associati law firm.

In 2004 she crossed the bridge, moving to an in-house role by joining RCS MediaGroup S.p.A., an international multimedia publishing company, listed on the Italian Stock Exchange, where she focused her activity in the areas of corporate governance, corporate and commercial law matters as well as M&A transactions. Within RCS Group, she was assigned with increasing responsibilities, and, at the end of 2009, she was entrusted with the responsibility of the Corporate Law Department of Dada S.p.A., an Italian listed digital service leader. At the end of 2010 she joined Recordati and since then, as Corporate Law Counsel, she has been advising the Group on all aspects relating to corporate governance matters, compliance with securities laws, corporate law in general as well as on extraordinary finance related transactions of the Group. Till 2019 she also supported the Group in M&A deals, contributing to the acquisition of several companies.

In April 2023, in addition to her role as Corporate Law Counsel, she was appointed Secretary of the Board of Directors of Recordati S.p.A..

Eugenia Litz

Vice President, Head of Investor Relations

Eugenia Litz joined Recordati as Vice President of Investor Relations in January 2024 and has over 15 years of experience in healthcare investor relations.


Her experience ranges from U.S. small and mid-cap biotech at BioMarin Pharmaceutical and ADC Therapeutics to mid- and large-cap European pharmaceuticals at AstraZeneca and Ipsen. She has worked across a range of therapeutic areas including rare diseases, oncology, respiratory, cardiovascular and neuroscience.

Eugenia started her career as a healthcare equity research analyst at Thomas Weisel Partners and has a BA from Northwestern University in Physiology.


The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.


In any event we assure you that your data will be processed solely for the above purposes and using the above methods.


The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.


A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).


Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.


In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.


Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.